Welcome to our dedicated page for Hyperion DeFi SEC filings (Ticker: HYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hyperion DeFi, Inc. (NASDAQ: HYPD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. Hyperion DeFi’s filings describe its evolution from an ophthalmic technology company into a Hyperliquid-native DeFi business that builds and deploys a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain, while continuing development of its Optejet User Filled Device.
Investors can review Form 8-K current reports that detail material events such as at-the-market equity program amendments, Sales Agreements with investment banks, HAUS agreements with DeFi partners, and the Joint Validator Operators’ Agreement for the Kinetiq × Hyperion validator node. Other 8-K filings describe leadership changes, including appointments of key executives, and press releases furnishing quarterly financial results and investor presentations.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide a broader view of Hyperion DeFi’s business model, including its digital asset treasury strategy, revenue components such as staking rewards, validator commissions, yield enhancement, DeFi monetization, and ecosystem rewards, as well as its ongoing life sciences activities around the Optejet User Filled Device. Proxy statements on Schedule 14A can offer additional detail on governance, board composition, and executive compensation.
On Stock Titan, these filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping readers understand how new agreements, capital raises, or digital asset strategies may affect Hyperion DeFi’s operations and risk profile. Users can also review Form 4 insider transaction reports to see how directors and officers are trading HYPD shares, and use AI explanations to interpret complex disclosures without wading through full-text filings.
HYPERION DEFI, INC. Chief Financial Officer David R. Knox reported a disposition of shares tied to equity compensation. On the reported date, 20,831 shares of common stock were withheld at a stated price of $0.00 per share to satisfy tax withholding obligations from the vesting and settlement of a previously reported restricted stock unit grant. After this tax-withholding disposition, he directly held 307,119 shares of common stock.
Hyperion DeFi, Inc. received an amended Schedule 13G/A reporting that Forsakringsaktiebolaget Avanza Pension beneficially owns 1,125,785 shares of Common Stock, representing 9.88% of the class. The filing shows sole voting power of 1,125,785 shares and shared dispositive power of 1,125,785 shares. The amendment is signed by Marie Karlsfeldt on 04/01/2026.
Hyperion DeFi, Inc. is a Delaware company that combines a digital-asset treasury strategy centered on Hyperliquid’s HYPE token with development of its Optejet ophthalmic drug-delivery device. The company aims to give shareholders simplified exposure to the Hyperliquid ecosystem while continuing its eye-care technology business.
Hyperion accumulates and stakes HYPE, operates a “Kinetiq x Hyperion” validator, and uses liquid staking tokens and structured HYPE Asset Use Service (HAUS) agreements to generate fees and staking yield. As of late 2025, it also runs options strategies and a temporary HYPE use agreement, adding complexity, liquidity constraints and counterparty risk.
The 10-K highlights extensive risks: extreme HYPE price volatility, technological and governance issues on the Hyperliquid network, regulatory uncertainty (including potential securities-law and investment-company implications), custody and smart-contract vulnerabilities, and the illiquidity of digital assets versus cash. The company is also pursuing a non-binding letter of intent to monetize the Optejet device and had nine employees as of December 31, 2025.
Hyperion DeFi, Inc. reported its first full year under its new DeFi strategy, showing rapid but still small operating growth alongside very large digital-asset swings. Q4 2025 revenue was $496,229, up from $302,506 in Q3, while non-GAAP Adjusted Gross Profit rose 87% to $820,997.
Digital-asset volatility dominated results: Q4 Treasury Gains (Losses) were a loss of $36.8M versus an $11.9M gain in Q3, driving a Q4 net loss of $39.8M and full-year 2025 net loss of $45.3M on revenue of $813,455. Adjusted EBITDA was $(38.9)M in Q4.
At December 31, 2025, the company reported Gross HYPE Holdings of $47.8M and cash and equivalents of $6.4M, with Gross HYPE Holdings increasing to $73.9M by March 23, 2026. Management guides 2026 Adjusted Gross Profit of $4M–$6M, about four times 2025’s $1M. It also signed a letter of intent to monetize its Optejet ophthalmic device, with potential closing in Q2 2026.
Separately, the Board adopted Third Amended and Restated Bylaws, reducing the stockholder meeting quorum to one-third of shares entitled to vote and confirming that stockholder actions may be taken at meetings or by written consent.
Forsakringsaktiebolaget Avanza Pension reports beneficial ownership of 863,087 shares of Hyperion DeFi, Inc. common stock, representing 10.19% of the class as shown in this amendment.
The filing lists 863,087 shares of sole voting power and 863,087 shares of shared dispositive power. The signature date on the amendment is 03/02/2026.
Hyperion DeFi received an updated ownership report from Swedish insurer Forsakringsaktiebolaget Avanza Pension. The firm reports beneficial ownership of 841,843 shares of Hyperion DeFi common stock, representing 9.94% of the class as of the stated event date.
Avanza Pension has sole power to vote these 841,843 shares and shared power to dispose of the same amount. The shares are described as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Hyperion DeFi.
Hyperion DeFi received an updated large-shareholder disclosure from Swedish insurer Forsakringsaktiebolaget Avanza Pension. The filing reports beneficial ownership of 856,666 shares of Hyperion DeFi common stock, representing 10.11% of the class as of the reporting date.
Avanza Pension has sole power to vote these 856,666 shares and shared power to dispose of them. The firm states the holdings were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Hyperion DeFi.
Hyperion Defi, Inc. reported an equity award to its General Counsel, Robert Rubenstein. On January 12, 2026, he was granted 75,000 units of common stock with a reported price of $0 per share, increasing his beneficial ownership to 75,000 common shares reported as directly held.
According to the footnote, these units are restricted stock units (RSUs). Of the total, 37,500 RSUs are scheduled to vest on January 12, 2027, and the remaining 37,500 RSUs vest in four equal installments of 9,375 RSUs beginning three months after January 12, 2027 and then every three months until fully vested, conditioned on his continued employment through each vesting date.
Hyperion DeFi, Inc. filed an initial insider ownership report for its General Counsel, Robert Rubenstein. This Form 3 identifies him as an officer of the company and confirms that, as of the event date of 01/12/2026, he reports no securities beneficially owned in Hyperion DeFi, Inc. The filing also includes a power of attorney as an exhibit, authorizing the signing of such ownership reports on his behalf.
Hyperion DeFi, Inc. reported insider share purchases by a director. A Form 4 filing shows open-market buys of 18,742 shares of common stock on 12/18/2025 at a volume-weighted average price of $3.1389 per share and an additional 19,702 shares at a volume-weighted average price of $3.1385 per share. These prices reflect multiple trades executed between $3.04 and $3.22 per share. Following these transactions, the reporting person beneficially owns 75,448 shares directly and 95,150 shares indirectly through a spouse.